We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The drug price “negotiations” in the 2022 Inflation ... At the same time, the political appeal of Medicare reducing drug prices is significant. The optics of wiping out the price-setting ...

Medicare has already completed negotiations for the first 10 drugs ... "The first round of Medicare drug price negotiation made it clear that this process will reduce the prices of these important ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

In what appears to be a response to manufacturer complaints regarding “black box” Inflation Reduction Act (IRA) drug price negotiations, the ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.